BioNanoSim

Company Overview

Snapshot

Founded in July 2015 by Simon Benita, BioNanoSim operates with 1–10 employees. The company has raised $6,000,000 across one funding round. BioNanoSim is recognized for its drug-delivery technology that deposits polymeric biodegradable nanoparticles into the body.

Business overview

BioNanoSim (BNS) is a Health Tech & Life Sciences company focused on Pharmaceuticals, specializing in Drug Delivery and Medical Cannabis. The company has developed a proprietary technology platform for the nano-encapsulation of drugs to enhance their delivery profile and therapeutic performance. BioNanoSim's technology is applied across various therapeutic areas, including oncology, ophthalmology, and metabolic diseases, and is also utilized for developing topical and ocular cannabis-based products.

Strategic signal

In January 2016, Immune Pharmaceuticals announced new data regarding topical cyclosporine nano-capsules in dermatology, highlighting the potential of nano-encapsulation technologies in improving drug delivery. This signals a growing industry interest in advanced drug delivery methods and validates the strategic importance of BioNanoSim's core technology in enhancing therapeutic outcomes and expanding treatment applications.

Company Intelligence Q&A

What is BioNanoSim's core technology?

BioNanoSim has developed a proprietary technology platform for the nano-encapsulation of drugs, designed to improve their delivery profile and therapeutic performance across various medical applications.

When was BioNanoSim founded and by whom?

BioNanoSim was founded in July 2015 by Simon Benita, who serves as the Founder & Chairman.

What therapeutic areas does BioNanoSim's technology address?

BioNanoSim's nano-encapsulation technology has demonstrated potential in designing innovative routes of administration across therapeutic areas including oncology, ophthalmology, and metabolic diseases.

What is BioNanoSim's involvement with cannabis-based products?

BioNanoSim utilizes its nano-encapsulation technologies to develop topical and ocular cannabis-based products, expanding its application beyond traditional pharmaceuticals.

What significant data was announced regarding nano-capsules in dermatology?

In January 2016, Immune Pharmaceuticals announced new data with topical cyclosporine nano-capsules in dermatology, showcasing the potential of such technologies in improving dermatological treatments.